Predictive Models of Treatment Responses and Survival Outcomes in Patients With Soft Tissue Sarcoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Soft Tissue Sarcoma
- Sponsor
- West China Hospital
- Enrollment
- 800
- Locations
- 1
- Primary Endpoint
- Progression-free survival outcomes
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
The aim of this study was to developed and validated models to predict therapeutic responses and patients' survivals in patients with soft tissue sarcoma and compared these models with currently available models.
Detailed Description
We performed a retrospective-prospective cohort study with the aim of developing and validating comprehensive models to predict treatment responses and survival outcomes in patients with biopsy-proven soft tissue sarcoma. Secondly, we aimed to compare the predictive accuracy with currently available noninvasive model.
Investigators
Yuhan Yang
Associate Professor
West China Hospital
Eligibility Criteria
Inclusion Criteria
- •Receiving no treatment before diagnosis
- •With written informed consent
Exclusion Criteria
- •Clinical data missing
- •Without written informed consent
Outcomes
Primary Outcomes
Progression-free survival outcomes
Time Frame: At least 5-year follow up
The endpoint was defined as the occurrence of progression or recurrence, or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence, or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed.
Overall survival outcomes
Time Frame: At least 5-year follow up
The endpoint was defined as the occurrence of death or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed.
Treatment response
Time Frame: At least 1-year follow up
The primary outcome was the evaluation of treatment response to individualized therapy in patients with soft tissue sarcoma.